The Regenerative Medicine Laboratory: Facilitating Stem Cell Therapy for Equine Disease

Borjesson, Dori L.; Peroni, John F.

doi:10.1016/j.cll.2010.12.001

Cited by 41 publications

(29 citation statements)

References 113 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Most canine experimental and clinical studies use BM-derived and adipose tissue-derived MSCs, since these are best characterized and are relatively comparable (Fortier & Travis 2011;Kisiel et al 2012;Takemitsu et al 2012). A distinction should be made between non-expanded, patient-side, autologous products such as BM concentrate and adiposederived stromal vascular fraction on the one hand and culture-expanded, autologous or allogeneic products including BM-MSCs and adipose tissue-derived MSCs on the other hand (Borjesson & Peroni 2011). Advantages of the non-expanded cell products include the heterogenicity of the cell populations and the possibility of directly injecting the product without a preceding cell culture step (Borjesson & Peroni 2011;Fortier & Travis 2011).…”

Section: Sources Of Canine Mesenchymal Stem Cellsmentioning

confidence: 99%

“…A distinction should be made between non-expanded, patient-side, autologous products such as BM concentrate and adiposederived stromal vascular fraction on the one hand and culture-expanded, autologous or allogeneic products including BM-MSCs and adipose tissue-derived MSCs on the other hand (Borjesson & Peroni 2011). Advantages of the non-expanded cell products include the heterogenicity of the cell populations and the possibility of directly injecting the product without a preceding cell culture step (Borjesson & Peroni 2011;Fortier & Travis 2011). Culture-expanded cells are highly enriched in MSCs.…”

Section: Sources Of Canine Mesenchymal Stem Cellsmentioning

confidence: 99%

“…Culture-expanded cells are highly enriched in MSCs. However, MSC expansion can take two to three weeks, which precludes their use for acute injuries (Borjesson & Peroni 2011). BM in dogs can be easily and relatively non-invasively obtained and is usually aspirated either from the proximal humerus, the proximal femur or the tuber coxae using a 15-or 16-gauge Jamshidi biopsy needle (Bruder et al 1998;Crovace et al 2008;Fortier & Travis 2011) (Figure 1).…”

Section: Sources Of Canine Mesenchymal Stem Cellsmentioning

confidence: 99%

“…However, preclinical efficacy and safety testing of novel treatments for humans must be evaluated using two animal species, i.e. first a rodent species (preferably rats) and second a non-rodent large animal that has closer similarities to humans (Borjesson & Peroni 2011). For research on MSCs for applications in humans, dogs are recognized to be superior to rodents.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Canine mesenchymal stem cells: state of the art, perspectives as therapy for dogs and as a model for man

Bakker

Ryssen

Schauwer

et al. 2013

Veterinary Quarterly

View full text Add to dashboard Cite

Interest in mesenchymal stem cells (MSCs) both for regenerative and reparative therapies in dogs is emerging, as the current treatment options for several conditions often do not result either in the desired clinical outcome or in the patients' return to normal function. In addition, canine MSCs have been evaluated in some experimental and preclinical studies on efficacy and safety testing of novel treatments for humans, since the dog is considered to be a superior model for humans than rodents. Although these MSCs can be derived from several sources, clinical use has favoured bone marrow and adipose tissue because of their relative ease of stem cell recovery and the minimal donor-site morbidity. Before any type of stem cell can be applied clinically, its unequivocal characterization by a set of specific functional or phenotypic markers is crucial. However, no uniform characterization criteria are available for canine MSCs so far. Moreover, although multi-lineage potential of canine MSCs has been demonstrated in a limited number of studies, research on the differentiation potential of MSCs towards tenocytes is still lacking in canine medicine. In contrast, this latter subject has been explored already in human as well as in equine medicine, demonstrating the need for a specific 'niche', i.e. factors with a positive influence on the MSC differentiation. Since most of these factors are still unknown regarding canine MSC, critical basic knowledge is urgently required to motivate and correctly translate the potential therapeutic applications of these stem cells in both dog and man.

show abstract

Section: Sources Of Canine Mesenchymal Stem Cellsmentioning

confidence: 99%

Section: Sources Of Canine Mesenchymal Stem Cellsmentioning

confidence: 99%

Section: Sources Of Canine Mesenchymal Stem Cellsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Canine mesenchymal stem cells: state of the art, perspectives as therapy for dogs and as a model for man

Bakker

Ryssen

Schauwer

et al. 2013

Veterinary Quarterly

View full text Add to dashboard Cite

show abstract

“…It is also noteworthy that such adult tissue -derived stem cell regenerative cell therapies are advancing rapidly in veterinary medicine where there is less regulatory stringency. For example, adult stem cell therapies for equine articular cartilage restoration and chondrogenesis have been shown to improve clinical symptoms (Borjesson and Peroni 2011).…”

Section: Mesenchymal Stem Cell Autologous and Allogeneic Cell Therapiesmentioning

confidence: 99%

Regenerative Medicine: Transforming the Drug Discovery and Development Paradigm

Karathanasis¹

2014

Cold Spring Harbor Perspectives in Medicine

View full text Add to dashboard Cite

Despite the explosion of knowledge in basic biological processes controlling tissue regeneration and the growing interest in repairing/replacing diseased tissues and organs through various approaches (e.g., small and large molecule therapeutics, stem cell injection, tissue engineering), the pharmaceutical industry ( pharma) has been reluctant to fully adopt these technologies into the traditional drug discovery and research and development (R&D) process. In this article, I discuss knowledge-base gaps and other possible factors that may delay full incorporation of these innovations in pharma R&D. I hope that this discussion will illuminate key issues that currently limit synergistic relationships between pharma and academic institutions and may even stimulate initiation of such collaborative research.B reakthroughs in stem cell biology and the clinical evaluation of regenerative therapeutics offer an unprecedented opportunity to transform traditional pharma research and development (R&D) and revolutionize future medical practice. Capitalizing on these opportunities will require a significant transformation in the pharma R&D model, including a shift in the way pharma and academic institutions interact.Although scientific breakthroughs are driven mostly by academic institutions, conversion of novel biologic insights into successful medical products is dependent on the drug development and distribution infrastructure available in traditional pharma. In this context, successful, purpose-driven innovation at the academia -pharma interface necessitates mutual understanding of the several factors including: general philosophy, long-term vision, operational and cultural paradigms, and key drivers and stressors across both of these enterprises.To describe how emerging technologies in regenerative medicine could transform pharma R&D and revitalize this entire business sector, I will first outline the current pharma R&D business environment and the manner in which this environment is creating the need for change in the prevailing business model.It has been argued that the current pharmaceutical business model is not sustainable because of the productivity crisis in pharma R&D (Pammolli et al. 2011). Many factors are responsible including escalating R&D costs, increased pressures for improved performance drugs, increased payer pressures, excessive regulatory stringency, increased focus on high-risk research involving complex therapeutic targets, and an over-reliance on "molecular reductionEditors:

show abstract